Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) to Issue $0.24 Dividend

Key Points

• Orion OYJ has declared a dividend of $0.24 per share, which will be paid to shareholders on November 7, following an ex-dividend date of October 16.
• The company reported earnings of $0.33 per share for the last quarter, with revenue totaling $472.57 million and a net margin of 22.61%.
• Analysts have downgraded Orion OYJ’s stock rating from "strong-buy" to "hold," indicating a cautious outlook for the company moving forward.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) declared a dividend on Saturday, October 4th, investing.com reports. Shareholders of record on Friday, October 17th will be given a dividend of 0.2418 per share on Friday, November 7th. This represents a yield of 127.0%. The ex-dividend date is Thursday, October 16th.

Orion OYJ Price Performance

ORINY opened at $37.29 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.86 and a debt-to-equity ratio of 0.15. The stock has a market cap of $10.53 billion, a price-to-earnings ratio of 25.37 and a beta of 0.09. Orion OYJ has a twelve month low of $21.95 and a twelve month high of $41.60. The company's 50-day moving average price is $39.10 and its two-hundred day moving average price is $35.25.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last released its earnings results on Friday, July 18th. The company reported $0.33 earnings per share for the quarter. The firm had revenue of $472.57 million for the quarter. Orion OYJ had a net margin of 22.61% and a return on equity of 38.68%. As a group, equities analysts expect that Orion OYJ will post 1.18 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Orion OYJ from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 8th. Two analysts have rated the stock with a Hold rating, According to MarketBeat, Orion OYJ has an average rating of "Hold".

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.